Make your diabetic patients walk: long-term impact of different amounts of physical activity on type 2 diabetes C Di Loreto, C Fanelli, P Lucidi, G Murdolo, A De Cicco, N Parlanti, ... Diabetes care 28 (6), 1295-1302, 2005 | 367 | 2005 |
Validation of a counseling strategy to promote the adoption and the maintenance of physical activity by type 2 diabetic subjects C Di Loreto, C Fanelli, P Lucidi, G Murdolo, A De Cicco, N Parlanti, ... Diabetes care 26 (2), 404-408, 2003 | 320 | 2003 |
Insulin is required for prandial ghrelin suppression in humans G Murdolo, P Lucidi, C Di Loreto, N Parlanti, A De Cicco, C Fatone, ... Diabetes 52 (12), 2923-2927, 2003 | 296 | 2003 |
Effects of whole-body vibration exercise on the endocrine system of healthy men C Di Loreto, A Ranchelli, P Lucidi, G Murdolo, N Parlanti, A De Cicco, ... Journal of endocrinological investigation 27, 323-327, 2004 | 224 | 2004 |
Ghrelin is not necessary for adequate hormonal counterregulation of insulin-induced hypoglycemia P Lucidi, G Murdolo, C Di Loreto, A De Cicco, N Parlanti, C Fanelli, ... Diabetes 51 (10), 2911-2914, 2002 | 200 | 2002 |
Metabolic response to exercise P De Feo, C Di Loreto, P Lucidi, G Murdolo, N Parlanti, A De Cicco, ... Journal of endocrinological investigation 26, 851-854, 2003 | 142 | 2003 |
Contribution of post-prandial versus interprandial blood glucose to HbA1c in type 1 diabetes on physiologic intensive therapy with lispro insulin at mealtime GBB M. Ciofetta, C. Lalli, P. Del Sindaco, E. Torlone, S. Pampanelli, M ... Diabetes Care 22 (795-800), 1999 | 125 | 1999 |
Exercise and diabetes P De Feo, C Di Loreto, A Ranchelli, C Fatone, G Gambelunghe, P Lucidi, ... Acta Biomed 77 (Suppl 1), 14-17, 2006 | 100 | 2006 |
Metabolic and endocrine effects of physiological increments in plasma ghrelin concentrations P Lucidi, G Murdolo, C Di Loreto, N Parlanti, A De Cicco, C Fatone, ... Nutrition, metabolism and cardiovascular diseases 15 (6), 410-417, 2005 | 80 | 2005 |
Meal intake similarly reduces circulating concentrations of octanoyl and total ghrelin in humans P Lucidi, G Murdolo, C Di Loreto, N Parlanti, A De Cicco, A Ranchelli, ... Journal of Endocrinological Investigation 27, RC15-RC15, 2004 | 52 | 2004 |
The clinical reality of guidelines for primary prevention of cardiovascular disease in type 2 diabetes in Italy. ZI Vaccaro O, Boemi M, Cavalot F, De Feo P, Miccoli R, Patti L, Rivellese AA ... Atherosclerosis 198 (2), 396-402, 2008 | 51 | 2008 |
Diabetes and exercise F Santeusanio, C Di Loreto, P Lucidi, G Murdolo, A De Cicco, N Parlanti, ... Journal of endocrinological investigation 26, 937-940, 2003 | 29 | 2003 |
Feasibility and effectiveness in clinical practice of a multifactorial intervention for the reduction of cardiovascular risk in patients with type 2 diabetes: the 2-year … ZI Vaccaro O, Franzini L, Miccoli R, Cavalot F, Ardigò D, Boemi M, De Feo P ... Diabetes Care 36 (9), 2566-72, 2013 | 27 | 2013 |
Fine needle aspiration coupled with real-time PCR: a painless methodology to study adaptive functional changes in skeletal muscle M Guescini, C Fatone, L Stocchi, C Guidi, L Potenza, M Ditroilo, ... Nutrition, metabolism and cardiovascular diseases 17 (5), 383-393, 2007 | 25 | 2007 |
Transforming growth factor-ß1 is more expressed in thyroid follicular adenoma than in normal tissue P Morosini, A Taccaliti, C Di Loreto, G Arnaldi, E Faloia, G Giacchetti, ... Journal of endocrinological investigation 17, 335-340, 1994 | 23 | 1994 |
Circulating ghrelin levels of visceral obese men are not modified by a short-term treatment with very low doses of GH replacement G Murdolo, P Lucidi, C Di Loreto, N Parlanti, A De Cicco, C Fanelli, ... Journal of endocrinological investigation 26, 244-249, 2003 | 20 | 2003 |
Once‐weekly semaglutide use in patients with type 2 diabetes: real‐world data from the SURE Italy observational study R Napoli, C Berra, AM Catarig, C Di Loreto, E Donatiello, TL Berentzen, ... Diabetes, Obesity and Metabolism 25 (6), 1658-1667, 2023 | 14 | 2023 |
Effectiveness in real world of once weekly semaglutide in people with type 2 diabetes: Glucagon-like peptide receptor agonist naïve or switchers from other glucagon-like … C Di Loreto, V Minarelli, G Nasini, R Norgiolini, P Del Sindaco Diabetes Therapy 13 (3), 551-567, 2022 | 14 | 2022 |
Impact of insulin degludec in type 2 diabetes: real-world data on effectiveness and safety P Ponzani, C Berra, A Di Lelio, P Del Sindaco, C Di Loreto, F Reggiani, ... Diabetes Therapy 9, 2209-2218, 2018 | 14 | 2018 |
Switching patients with type 1 diabetes to insulin degludec from other basal insulins: real-world data of effectiveness and safety P Ponzani, C Berra, A Di Lelio, P Del Sindaco, C Di Loreto, F Reggiani, ... Diabetes Therapy 11, 97-105, 2020 | 13 | 2020 |